Particle engineering techniques for inhaled biopharmaceuticals

Advanced Drug Delivery Reviews

Volumn 58, Issue 9-10, 2006, Pages 1009-1029

  Shoyele, Sunday A ^a   Cawthorne, Simon ^a  

^a 3M Drug Delivery Systems   (United Kingdom)

Author keywords

Aerodynamic diameter; Biopharmaceuticals; Particle engineering; Protein peptide; Spray drying; Supercritical fluid

Indexed keywords

AERODYNAMICS; COST EFFECTIVENESS; DEPOSITION; DRYING; PROTEINS; PULMONARY DISEASES; SUPERCRITICAL FLUIDS;

AERODYNAMIC DIAMETER; BIOPHARMACEUTICALS; PEPTIDES; SPRAY DRYING;

DRUG PRODUCTS;

BETA INTERFERON; CARBON DIOXIDE; CETRORELIX; CHITOSAN; CYCLOSPORIN A; DORNASE ALFA; HUMAN GROWTH HORMONE; INFLUENZA VACCINE; INSULIN; LACTATE DEHYDROGENASE; LEUPRORELIN; LYSOZYME; MACROGOL; MANNITOL; OVALBUMIN; PARATHYROID HORMONE; POLYMER; POLYSORBATE 20; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SALCATONIN; TRYPSINOGEN;

BIOMEDICAL ENGINEERING; CONFORMATION; COST EFFECTIVENESS ANALYSIS; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ELECTRICITY; FREEZE DRYING; LIQUID; MEDICAL TECHNOLOGY; METERED DOSE INHALER; NEBULIZATION; PARTICLE SIZE; POWDER; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SAFETY; SOLVENT EXTRACTION; SPRAY DRYING; SUSTAINED DRUG RELEASE;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; HUMANS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33750804217     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.07.010     Document Type: Review

References (134)

1. Walsh G. Biopharmaceuticals and biotechnology medicines: an issue of nomenclature. Eur. J. Pharm. Sci. 15 (2002) 135-138
2. Walsh G. Second generation biopharmaceuticals. Eur. J. Pharm. Biopharm. 58 (2004) 185-196
3. Johnson I. Human insulin from recombinant DNA technology. Science 291 (2004) 632-637
4. Fielder J., Wagner N., Grammaticos S., Hoffman H., Kaufmann H., and Otto R. Use of flow-cytometric analysis to optimize cell banking strategies for production of biopharmaceuticals from mammalian cells. J. Biotechnol. 120 (2005) 111-120
5. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol. 23 (2005) 553-558
6. Bagger Y., Tanko L.B., Alexadersen P., Karsdal M.A., Olson M., Mindeholm L., Azria M., and Christiansen C. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in post menopausal women: a new potential treatment of osteoarthritis. Bone 33 (2005) 425-430
7. Zheng Y.J., and Fulu M. Decrease of genital organ weights and plasma testosterone in rat following oral administration of leuprolide microemulsion. Int. J. Pharm. 307 (2006) 209-215
8. Cullander C., and Guy R.H. Routes of delivery: case studies (6), transdermal delivery of peptides and proteins. Adv. Drug Deliv. Rev. 8 (1992) 291-329
9. Edman P., and Bjork E. Routes of delivery: case studies (1), nasal delivery of peptide drugs. Adv. Drug Deliv. Rev. 8 (1992) 165-177
10. Harris D., Liaw J.H., and Robinson J.R. Routes of delivery: case studies (7) ocular delivery of peptide and protein drugs. Adv. Drug Deliv. Rev. 8 (1992) 331-339
11. Ho N.F.N., Barsutin C.L., Burton P.S., and Merckle H.P. Routes of delivery: case studies (3), mechanistic insights to buccal delivery of proteinaceous substance. Adv. Drud Deliv. Rev. 8 (1992) 197-235
12. Smith P.L., Wall D.A., Gochoco C.H., and Wilson G. Routes of delivery: case studies (5), oral absorption of peptides and proteins. Adv. Drug Deliv. Rev. 8 (1992) 253-290
13. Codrons V., Vanderbist F., Vanbeeck R.K., Arras M., Lison D., Preat V., and Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powder in rats. J. Pharm. Sci. 92 (2003) 938-948
14. Hollinger M.A. Respiratory pharmacology and toxicology (1994), W. B., Saunders, Philadelphia 1-20
15. Byron P.R. Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv. Drug Deliv. Rev. 5 (1990) 107-132
16. Purewal T.S. Formulation of metered dose inhalers. In: Purewal T.S., and Grant D.J.W. (Eds). Metered Dose Inhaler Technology (1998), Interpharm, Illinois 9-68
17. Kompella U.B., and Lee V.H. Delivery systems for the penetration enhancement of peptide and protein drugs: design consideration. Adv. Drug Deliv. Rev. 46 (2001) 211-245
18. Sorokin S.P. A morphological and cytochemical study of the great alveolar cell. J. Histochem. Cytochem. 14 (1961) 884-897
19. Garcia-Conteras L., Jones L.D., and Hickey A.J. Alveolar macrophages as a target for drug delivery. Res. Drug Deliv. IX (2004) (California)
20. Liu J., Wong H., Moselly J., Bowen B., Wu X.Y., and Johnston M.R. Targeting colloidal particulates to thoracic lymph nodes. Lung Cancer 51 (2006) 377-386
21. Corkery K. Inhalable drugs for systemic therapy. Respir. Care 45 (2000) 831-835
22. Hussain A., Arnold J.J., Khan M.A., and Ahsan F. Absorption enhancers in pulmonary delivery. J. Control. Release 94 (2004) 15-24
23. M. Hanna, P. York. Method and apparatus for the formation of particles. European Patent 0706421B1, 1998.
24. Quinn E.A., Forbes R.T., Williams A.C., Oliver M.J., McKenzie L., and Purewal T. Protein conformational stability in the hydrofluoroalkane propellants tetraflouroethane and heptafluoropropane analysed by Fourier transform Raman spectroscopy. Int. J. Pharm. 186 (1999) 31-41
25. Johnson K.A. Preparation of peptide and protein powders for inhalation. Adv. Drug Deliv. Rev. 26 (1997) 3-15
26. Phillips E., Allsopp E., Christensen T., Fitzgerald M., and Zhao L. Size reduction of peptides and proteins by jet milling. In: Dalby R.N., Byron P.R., and Farr S.J. (Eds). Proceeding of RDD vol. VI (1998), Interpharm, Buffalo 161-168
27. Willis R.C. Crystallize to deliver. Mod. Drug Discov. (2003) 12 (March)
28. Hallworth G.W. The formulation and evaluation of pressurized metered dose inhalers. In: Ganderton D., and Jones T.M. (Eds). Drug Delivery to the Respiratory Tract (1987), Ellis Horwood, Chistester 87-118
29. Snow R.H., Kaye B.H., Capes C.E., and Sresty G.C. Size reduction and size enlargement. In: Perry R.H., and Green D. (Eds). Perry's Chemical Engineer's Handbook (1984), McGraw Hill, New York 1-59
30. Van Vlack L.H. Elements of Materials Science and Engineering (1980), Addison Wesley Publishing, Reading 185-208
31. Adjei A. Pulmonary bioavailability of peptide drugs: animal models, preclinical studies and clinical studies. Presented at Respiratory Drug Delivery II (1990), Keystone, Co
32. Schlocker W., GschlieBer S., and Bernkop-Schniirch A. Evaluation of the potential of air jet milling of solid protein-poly(acrylate) complexes for microparticle preparation. Euro J. Pharm. Biopharm. 62 (2006) 260-266
33. Zijlstra G.S., Hinrichs W.L.J., deBoer A.H., and Frijlink H.W. The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix. Eur. J. Pharm. Sci 23 (2004) 139-149
34. Adjei A., Sundberg D., Miller J., and Chin A. Bioavailability of leuprolide acetate following nasal and inhalation delivery to the rats and healthy humans. Pharm. Res. 9 (1992) 244-249
35. K.G. Backstrom, C.M. Dahlback, P. Edman, A.C.B. Johansson, Therapeutic preparation for inhalation. International Patent Application (1995) WO 95/00127.
36. K. Tomihisa, Grinding of rubber below the brittle temperature with supersonic jet air. Japanese Patent (1973) JP73103614.
37. Kobayashi S., Kondo S., and Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhances in rats. Pharm. Res. (1996) 80-83
38. Hinrichs W.L.J., De Smelt N.N., Demeester J., and Frijlink H.W. Insulin is a promising cryo- and lyoprotectant for PEGylated lipoplexes. J. Control. Release 103 (2005) 465-479
39. Ohtake S., Schebor C., Palecek S.P., and de Pablo J.J. Phase behaviour of freeze-dried phospholipid-cholesterol mixtures stabilized with trehalose. Biochim. Biophys. Acta, Biomembr. 1713 (2005) 57-64
40. R.M. Platz, J. Utsum, Y. Satoh, N. Naruse, Pharmaceutical aerosol formulation of solid polypeptide microparticles and method for the preparation thereof. International Patent Application (1991) WO 91/16038.
41. R.M. Platz, A. Ip, C.L. Whitham, Process for preparing micronized polypeptide drugs. US Patent (1994) 5354562.
42. A.L. Adjei, E.S. Johnson, J.W. Kesterson, LHRH analog formulations, US Patent (1990) 4897256.
43. Lizio R., Damm M., Sarlikiotis A.W., Bauer H.H., and Lehr C.M. Low temperature micronization of a peptide drug in a fluid propellant: case study cetrorelix. AAPS PharmSciTech 2 (2001) 1-7
44. Irngartinger M., Camuglia V., Damm M., Goede J., and Frijlink J. Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. Eur. J. Pharm. Biopharm. 58 (2004) 7-14
45. Masters K. Spray Drying Handbook (1991), Longman Scientific and Technical, Essex, England
46. Broadhead J., Rouan S.K.F., Hau I., and Rhodes C.T. The effect of process and formulation variable on the properties of spray dried β-galactosidase. J. Pharm. Pharmacol. 46 (1994) 458-467
47. Labrude P., Rasolomanana M., Vigneron C., Thiron C., and Chailott B. Protective effect of sucrose on spray drying of oxyhemoglobin. J. Pharm. Sci. 78 (1989) 223-229
48. Brandenberger H. Best@buchi evaporation. Inf. Bull. 27 (2003)
49. Chan H.K. Dry powder aerosol drug delivery - opportunities for colloid and surface scientists. Colloids and Surfaces A: Physicochem. Eng. Aspects 284-285 (2006) 50-55
50. Bittner B., and Kissel T. Ultra atomization for spray drying: a versatile technique for the preparation of protein loaded biodegradable microspheres. J. Microencapsul 16 (1999) 325-341
51. Maa Y.F., Nguyen P.A., Andya J.D., Sweeney T.D., Shire S.J., and Hsu C.C. Effects of spray drying and subsequent processing on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm. Res. 15 (1998) 768-775
52. J.S. Patton, L.C. Foster, R.M. Platz, Methods and composition for pulmonary delivery of insulin. International patent application, WO95/ 24183.
53. Niven R.W., Lott F.D., Ip A.Y., and Cribbs J.M. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor. Pharm. Res 11 (1994) 1101-1109
54. A.D. Sutton, R.A. Johnson, P.J. Senior, D. Heath, Preparation of diagnostic agents. European patent application (2000) 0681843A2.
55. Willaya-Areekul S., Needham G.F., Milton N., Roy M.L., and Nail S.L. Freeze-drying of tert-butanol/water co-solvent system: a case report on formation of a friable freeze dried powder of tobramycin sulphate. J. Pharm. Sci. 91 (2002) 1147-1155
56. Chan H., Lechuga-Ballesteros D., Vehring R., Foss W.R., Feeley J.C., and Clark A. Effect of bulk and surface properties on the aerosol performance of dry powders for inhalation. Presented at 2002 AAPS, Annual Meeting and Exposition, Nov. 10-14 (2002), Canada, Toronto, Ontario
57. Chan H.K., Clark A., Gonda I., Mumenthaler M., and Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 14 (1997) 431-437
58. Liao Y.-H., Brown M.B., Jones S.A., Nazir T., and Martin G.P. The effect of polyvinyl alcohol on the in-vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. Int. J. Pharm. 304 (2005) 29-39
59. Codrons V., Vanderbist F., Verbeeck R., Mohammed A., Lison D., Preat V., and Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powder in rats. J. Pharm. Sci. 92 (2003) 938-950
60. J.D. Andya, Y.F. Maa, H.R. Costantino, P.A. Nguyen, N. Dasovich, T.D. Sweeney, C.C. Hsu, S.J. Shire, The effect of formulation excipients on protein stability and aerosol performance of spray dried powders of a recombinant humanized anti-IgE monoclonal antibody, Pharm. Res. 16 (3) 350-358.
61. Bosquillon C., Preat V., and Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Release 96 (2004) 233-244
62. Adler M., Unger M., and Lee G. Surface composition of spray dried particles of bovine serum albumin/trehalose/surface. Pharm. Res. 17 (2000) 863-870
63. Leach C.L., Patton J.S., Perkins K.M., Kwo M.C., Bueche B., Guo L., and Bentley M.D. Dry powder formulation of inhaled PEG-Insulin yields prolonged systemic activity in dogs. Presented at the American Diabetes Association 63rd Scientific Session, June (2003), Louisiana, New Orleans
64. Elversson J., and Millqvist-Fureby A. Aqueous two-phase system as a formulation concept for spray-dried protein. Int. J. Pharm. 294 (2005) 73-87
65. Dellamary L., Smith D.J., Bloom A., Bot S., Guo G.-R., Costello M., and Bot A. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J. Control. Release 95 (2004) 489-500
66. Grenha A., Seijo B., and Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25 (2005) 427-437
67. Calvo P., Remunan-Lopez C., Vita-Jato J.L., and Alonso M.J. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. 63 (1997) 125-132
68. Pasquali I., Bettini R., and Gordono F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Eur. J. Pharm. Sci. 27 (2006) 299-310
69. Sievers R.E., Karst U., Milewski P.D., Sellers S.P., Miles B.A., Schaefer J.D., Stoldt C.R., and Xu C.Y. Formation of aqueous small droplet aerosol assisted by supercritical carbon dioxide. Aerosol Sci. Technol. 30 (1999) 3-15
70. 2-assisted nebulization for the production and administration of drugs. J. Aerosol Sci. 27 (1996) S497-S498
71. Reverchon E., De Marco I., and Della Porta G. Rifampicin microparticles production by supercritical anti-solvent precipitation. Int. J. Pharm. 243 (2002) 83-91
72. 2-assisted nebulization of aqueous solutions. Proceeding of Resp. Drug Deliv., VI, South Carolina (1998) 417-419
73. 2-assisted aerosolization. J. Pharm. Sci. 90 (2001) 785-797
74. Sievers R.E., Huang E.T.S., Villa J.A., Walsh T.R., Meresman H.V., Liang C.D., and Cape S.P. Rapid gentle drying using dense carbon dioxide to form fine dry powders. Proceedings of Resp Drug Deliv: VIII. Tucson, Arizona (2002) 675-677
75. Sievers R.E., Huang E.T.S., Villa J.A., Kawamoto J.K., Evans M.M., and Brauner P.R. Low temperature manufacturing of fine pharmaceutical powders with supercritical fluid aerosolization in bubble dryer. Pure Appl. Chem. 73 (2001) 1299-1303
76. Dalby R.N., Naini V., and Byron P.R. Droplet drying and electrostatic collection, a novel alternative to conventional communition techniques. J. Biopharm. Sci. 3 (1992) 91-99
77. W.R. Gombotz, M.S. Healy, L.R. Brown, H.E. Auer, Process for producing small particles of biologically active molecules, European Patent Application (1994) EP0432232B1.
78. Maa Y.F., Nguyen P.A., Sweeny T., Shire S.J., and Hsu C.C. Protein inhalation powders. Spray drying vs spray freeze drying. Pharm. Res. 16 (1999) 249-254
79. Constantino H.R., Firouzabadian L., Hogeland K., Wu C., Banganski C., Cordova C.M., Carrasquillo K.G., Griebenow K., Zale S.E., and Tracy M.A. Protein spray freeze-drying. Effect of atomization conditions on particle size and stability. Pharm. Res. 17 (2000) 1374-1384
80. Constantino H.R., Firouzabadian L., Wu C., Carrasquillo K.G., Griebenwo K., Zale S.E., and Tracy M.A. Protein spray freeze-drying: 2. Effect of formulation variables on particle size and stability. J. Pharm. Sci. 91 (2002) 388-395
81. Webb S.D., Golledge S.T., Cleland J.T., Carpenter J.F., and Randolph T.W. Surface adsorption of recombinant human interferon-ã in lyophilized and spray-lyophilized formulations. J. Pharm. Sci. 91 (2002) 1474-1487
82. Heller M.C., Carpenter J.F., and Randolph T.W. Protein formulation and lyophilization cycle design: prevention of damage due to freeze-concentration induced phase separation. Biotechnol. Bioeng. 63 (1999) 166-174
83. DePaz R.A., Dale D.A., Barnett C.C., Carpenter J.F., Gaertner A.C., and Randolph W. Effects of drying methods and additives on the structure, function and storage stability of subtilisin: role of protein conformation and molecular mobility. Enzyme Microb. Technol. 31 (2002) 765-774
84. Yu Z., Johnston K.P., and Williams III R.O. Spray freezing into liquid versus spray-freeze drying: influence of atomization on protein aggregation and biological activity. Eur. J. Pharm. Sci. 27 (2006) 9-18
85. Roger T.L., Nelsen A.C., Hu J., Brown J.N., Sarkari M., Young T.J., Johnston K.P., and William III R.O. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur. J. Pharm. Biopharm. 54 (2002) 271-280
86. Yu Z., Rogers T.L., Hu J., Johnston K.P., and Williams III R.O. Preparation and characterization of microparticles containing peptide produced by a novel process: spray freezing into liquid. Eur. J. Pharm. Biopharm. 54 (2002) 221-228
87. Yu Z., Garcia A.S., Johnston K.P., and Williams R.O. Spray freezing into liquid for highly stable protein nanostructured microparticles. Eur. J. Pharm. Biopharm. 58 (2004) 529-537
88. 2. Chem. Eng. Sci. 61 (2006) 2880-2887
89. York P. Strategies for particle design using supercritical fluid technologies. PSST 2 (1999) 430-440
90. Tom J.W., and Debenedetti P.G. J. Aerosol Sci. 22 (1999) 555-584
91. Schmitt W.J., and Reid R.C. Fluid Phase Equilib. 32 (1986) 77-99
92. Weidner E. High-pressure chemical engineering. Process Technol. Proceedings vol. 12 (1996), Elservier
93. Tandya A., Dehghani F., and Foster N.R. Micronization of cyclosporine using dense gas technique. J. Supercrit. Fluids 37 (2006) 272-278
94. Krukonis V. Supercritical fluid nucleation of difficult to comminute solids. Proceedings of the Annual Meeting AlChE vol. 140 F (1984) T-214
95. Phillips E.M., and Stella V.J. Rapid expansion from supercritical solutions: applications to pharmaceutical processes. Int. J. Pharm. 94 (1993) 1-10
96. Mishinma K., Matsuyama K., Tanabe D., Yamauchi S., Young T.J., and Johnston K.P. Microencapsulation of protein by rapid expansion of supercritical solution with a non solvent. Material, Interfaces and Electrochemical Phenomena. AlChE Journal vol. 46 (2000) 857-865
97. Young T.J., Mawson S., Johnstone K.P., Henriksen I.B., Pace G.W., and Mishra A.K. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol. Prog. 16 (2000) 402-407
98. Jovanovic N., Bouchard A., Hofland G.W., Witkamp G., Crommelin D.J., and Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm. Res. 21 (2004) 1955-1969
99. Yeo S.D., Lim G.B., Debenedetti P.G., and Bernstein H. Formation of microparticulate protein powders using a supercritical fluid anti-solvent. Biotechnol. Bioeng. 41 (1993) 341-346
100. Jackson M., and Mantsch H.H. Beware of proteins in DMSO. Biochim. Biophys. Acta 1078 (1991) 231-235
101. 2. Proceedings of the 5th International Symposium on Supercritical Fluids, Atlanta (2000)
102. N.R. Foster, H.L. Regtop, F. Dehghani, R.T. Bustami, H.-K. Chan, Synthesis of small particles, WO Patent No: 0245690.
103. Thiering R., Dehghani F., Dillow A., and Foster N.R. The influence of operating conditions on the dense gas precipitation of model proteins. J. Chem. Technol. Biotechnol. 75 (2000) 29-41
104. Yeo S.D., Debenechi P.G., Radosz M., and Schmidt H.W. Supercritical anti-solvent process for substituted para-linked aromatic polyamides: phase equilibrium and morphology study. Macromolecules 26 (1993) 6207-6210
105. Yeo S.D., Lim G.B., Debenedetti P.G., and Bernstein H. Formation of microparticulate protein powders using a supercritical fluid anti-solvent. Biotechnol. Bioeng. 41 (1993) 341-346
106. Palakodaty S., and York P. Phase behaviour effects on particle formation process using supercritical fluids. Pharm. Res. 16 (1999) 976-985
107. Caliceti P., Salmaso S., Elvassore N., and Bertucco A. Effective protein release from PEG/PLA nanoparticles produced by compressed anti-solvent precipitation techniques. J. Control. Release 94 (2004) 195-205
108. 2 process. Int. J. Pharm 290 (2005) 73-81
109. 2. Pharm. Res. 12 (1995) 1211-1217
110. Falk R.F., and Randolph W.Th. Process variable implications for residual solvent removal and polymer morphology in the formation of gentamycin-loaded poly(l-lactide) microparticles. Pharm. Res. 15 (1998) 1233-1237
111. Perez deDiego Y., Pellikaan H.C., Wubbolts F.E., Borchard G., Witkamp G.J., and Jansens P.J. Opening new operating windows for protein micronization using the PCA process. J. Supercrit. Fluids 36 (2006) 216-224
112. P.G. Debenedetti, G. Lim, R.K. PrudHomme, Formation of protein microparticles by antisolvent precipitation. European patent application EP052314A1, 1993.
113. Yeo S., Lim G., Debenedetti P.G., and Bernestein H. Formulation of microparticulate protein powders using a supercritical fluid antisolvent. Biotechnol. Bioeng. 41 (1993) 341-346
114. Perez de Diego Y., van Rooijen M.B.P., Wubbolts F.E., and P.J. Effect of process parameters on microparticle formation by precipitation with compressed anti-solvent (PCA). Proceedings of Eighth International Workshop on Industrial Crystallization (2001) 98-104
115. Reverchon E., and DeMarco I. Supercritical antisolvent micronization of cefonicid, thermodynamic interpretation of results. J. Supercrit. Fluids 31 (2004) 207-215
116. Weber A., Yelash I.V., and Kraska T. Effect of the phase behaviour of the solvent-anti-solvent systems on the gas anti-solvent crystallization of paracetamol. J. Supercrit. Fluids 33 (2005) 107-113
117. Elkordy A.A., Forbes R.T., and Barry B.W. Integrity of crystalline lysozyme exceeds that of a spray dried form. Int. J. Pharm. 247 (2002) 79-90
118. Elkordy A.A., Forbes R.T., and Barry B.W. Stability of crystallised and spray dried lysozyme. Int. J. Pharm. 278 (2004) 209-219
119. Lee M.J., Kwon J.-H., Shin J.-S., and Kim C.-W. Microcrystallization of α-lactalbumin. J. Crystal Growth 282 (2005) 434-437
120. Jen A., and Merkle H.P. Pharm. Res. 18 (2001) 1483
121. Valder C., and Merrifield D. Pharmaceutical Technology. Smithkline Beecham R&D News vol. 32 (1996) 1
122. Krycer I., and Hersey J.A. A comparative study of communication in rotatory and vibratory ballmills. Powder Technol. 27 (1980) 137-141
123. Kwon J.-H., Lee B.-H., Lee J.-J., and Kim C.W. Insulin microcrystal suspension as a long acting formulation for pulmonary delivery. Eur. J. Pharm. Sci. 22 (2004) 107-116
124. Skyler J.S., Gelfand R.A., and Koirides I.A. Treatment of type 2 diabetes mellitus with inhaled human insulin: a 3 month, multicenter trial (abstract). Diabetes 47 (1998) A61 (suppl.)
125. Cefalu W.T., Gelfand R.A., and Koirides I.A. Treatment of type 2 diabetes mellitus with inhaled insulin: a 3 month, multicenter trial (abstract). Diabetes 47 suppl. (1998) A61
126. Patton J.S., Bukar J., and Nagarajan S. Inhaled insulin. Adv. Drug Deliv. Rev. 35 (1999) 235-247
127. Sanchez A., Villamayor B., Guo Y., Mclver J., and Alonso M.J. Formulation strategies for the stabilization of tetanus toxoid in poly(lactide co-glycolide) microspheres. Int. J. Pharm. 185 (1999) 255-266
128. Davey R.J., Blagden N., Potts G.D., and Docherty R. Polymorphism in molecular crystals: stabilization of a metastable form by conformational mimicry. J. Am. Chem. Soc. 199 (2000) 1767-1772
129. Zhang G.G.Z., Law D., Schmilt E.A., and Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv. Drug Deliv. Rev. 56 (2004) 371-390
130. P. York, Particle design, a 'supercritical' issue for the pharma industry, Pharm. Vision, (200) 28-30.
131. Edward A.D., Shekunov B.Y., Kordikowski A.I., Forbes R.T., and York P. Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDS). J. Pharm. Sci. 90 (2001) 1115-1124
132. Duddu S.P., Sick S.A., Walter Y.H., Tarara T.E., and T.R. Improved lung delivery from a passive dry powder inhaler using an engineered pulmosphere powder. Pharm. Res. 19 (2002) 689-695
133. de Boer A.H., Gjaltema D., Hagedoom P., Schaller M., Witt W., and Frijlink H.W. Design and application of a new modular adapter laser diffraction characterisation of inhalation aerosols. Int. J. Pharm. 249 (2002) 233-245
134. Vemavarapu C., Mollan M.J., Lodaya M., and Needham T.E. Design and process aspect of laboratory scale SCF particle formation systems. Int. J. Pharm. 292 (2005) 3